Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings)
Benzinga Insights 1 year ago
Analyst Ratings
Throughout the last three months, 7 analysts have evaluated Prothena Corp (NASDAQ:PRTA), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $15.14, a high estimate of $20.00, and a low estimate of $10.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 44.8%.
Breaking Down Analyst Ratings: A Detailed Examination
An in-depth analysis of recent analyst actions unveils how financial experts perceive Prothena Corp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew S. Fein | HC Wainwright & Co. | Raises | Buy | $20.00 | $14.00 |
| Jason Butler | JMP Securities | Lowers | Market Outperform | $11.00 | $29.00 |
| Yasmeen Rahimi | Piper Sandler | Lowers | Overweight | $15.00 | $81.00 |
| Rudy Li | Chardan Capital | Maintains | Buy | $18.00 | $18.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $10.00 | $18.00 |
| Andrew S. Fein | HC Wainwright & Co. | Maintains | Buy | $14.00 | $14.00 |
| Rudy Li | Chardan Capital | Maintains | Buy | $18.00 | $18.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Prothena Corp. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Prothena Corp compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Prothena Corp's stock. This analysis reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Prothena Corp's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Prothena Corp analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know Prothena Corp Better
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Key Indicators: Prothena Corp's Financial Health
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Challenges: Prothena Corp's revenue growth over 3M faced difficulties. As of 30 June, 2025, the company experienced a decline of approximately -96.65%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Prothena Corp's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -2845.41%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -33.01%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -28.12%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Prothena Corp's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.